Drugs / choline magnesium trisalicylate
choline magnesium trisalicylate
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00156299 | Mar 2003 → Jul 2008 | leukemia | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01009931 | Mar → Oct 2011 | leukemia | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
| Phase 2 | NCT02144675 | Jan 2009 → Apr 2016 | acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +8 | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | choline magnesium trisalicylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02144675 ↗ |
| Known as | Choline magnesium salicylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297727 ↗ |
| Known as | NSC-751675 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297727 ↗ |
| Known as | Trilisate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297727 ↗ |
| Action | Inhibit | “Choline magnesium trisalicylate +/- dexamethasone decreased nuclear NF-kappaB, whereas dexamethasone alone was associated with an increase in nuclear NF-kappaB in AML cells.” PMID 19010875 ↗ Nov 2008 |
| Route | Oral | “1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.” NCT00156299 ↗ |